DexCom, Inc. (NASDAQ:DXCM) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• DexCom, Inc. has received a consensus recommendation of "Moderate Buy" from 23 research firms, with an average target price of $97.42 for the next 12 months.
• Recent brokerage reports show target price adjustments; Robert W. Baird lowered their target from $112 to $90, while Raymond James raised it from $99 to $102.
• In its latest earnings report, DexCom reported an EPS of $0.48, exceeding estimates, and reported a 15.2% year-over-year revenue increase to $1.16 billion.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-three research firms that are currently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $97.4211.

A number of brokerages recently commented on DXCM. Robert W. Baird lowered their target price on DexCom from $112.00 to $90.00 and set an "outperform" rating for the company in a report on Friday, September 26th. Citigroup lowered their price objective on shares of DexCom from $105.00 to $85.00 and set a "buy" rating for the company in a research note on Tuesday. Raymond James Financial raised their price objective on shares of DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 31st. Morgan Stanley raised their price target on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Oppenheimer cut shares of DexCom from an "outperform" rating to a "market perform" rating in a research report on Monday, September 8th.

DexCom Stock Performance

NASDAQ:DXCM opened at $68.08 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock has a market capitalization of $26.70 billion, a P/E ratio of 47.28, a PEG ratio of 1.42 and a beta of 1.47. The company has a 50 day moving average price of $74.70 and a 200 day moving average price of $77.68. DexCom has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period last year, the business posted $0.43 earnings per share. The company's quarterly revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Equities research analysts forecast that DexCom will post 2.03 EPS for the current year.

Insider Buying and Selling

In other news, Director Kyle Malady sold 667 shares of DexCom stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the transaction, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the transaction, the executive vice president owned 94,102 shares of the company's stock, valued at $7,555,449.58. This represents a 0.53% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,849 shares of company stock valued at $564,733. 0.32% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Nuveen LLC purchased a new stake in shares of DexCom during the 1st quarter worth $554,893,000. Norges Bank purchased a new stake in shares of DexCom during the 2nd quarter worth $453,279,000. Groupama Asset Managment lifted its holdings in DexCom by 79,043.1% during the 2nd quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company's stock worth $350,601,000 after buying an additional 4,011,438 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of DexCom by 106.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company's stock worth $576,610,000 after acquiring an additional 3,410,858 shares in the last quarter. Finally, Jennison Associates LLC boosted its position in shares of DexCom by 37.7% during the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock worth $718,632,000 after acquiring an additional 2,879,489 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.